AstraZeneca, UVa align to slow atherosclerotic plaque development

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
AstraZeneca has partnered with the University of Virginia (UVa) to develop new treatments to fend off coronary artery disease (CAD) and peripheral vascular disease (PAD).

Under the terms of agreement, of which the financial terms were not released, the two parties will seek to identify biological targets that have been linked as starting points of CAD and PAD to ripen disease treatment measures.

According to the company, these lifestyle markers such as poor diet, obesity and sedentary lifestyles have been significantly linked to heart disease. Already, treatments such as nonsurgical approaches to managing CAD have been developed, due to increased need.

The company said that developing approaches, which slow the progression of and also regress atherosclerotic plaque, is vital in combating the disease. According to AstraZeneca, this is a multi-year agreement established to optimize care for CAD and PAD patients.